論文 - 詳細
| RRC ID | 71940 |
|---|---|
| 著者 | Hirase S, Aoki A, Hattori Y, Morimoto K, Noguchi K, Fujii I, Takatani-Nakase T, Futaki S, Kirihata M, Nakase I. |
| タイトル | Dodecaborate-Encapsulated Extracellular Vesicles with Modification of Cell-Penetrating Peptides for Enhancing Macropinocytotic Cellular Uptake and Biological Activity in Boron Neutron Capture Therapy. |
| ジャーナル | Mol Pharm |
| Abstract |
Boron neutron capture therapy (BNCT) is a radiation therapy for cancer. In BNCT, the internalization of boron-10 atoms by cancer cells induces cell death through the generation of α particles and recoiling lithium-7 nuclei when irradiated with low-energy thermal neutrons. In this study, we aimed to construct exosomes [extracellular vesicles (EVs)]-based drug delivery technology in BNCT. Because of their pharmaceutical advantages, such as controlled immune responses and effective usage of cell-to-cell communication, EVs are potential next-generation drug delivery carriers. In this study, we successfully developed polyhedral borane anion-encapsulated EVs with modification of hexadeca oligoarginine, which is a cell-penetrating peptide, on the EV membrane to induce the actin-dependent endocytosis pathway, macropinocytosis, which leads to efficient cellular uptake and remarkable cancer cell-killing BNCT activity. The simple and innovative technology of the EV-based delivery system with "cassette" modification of functional peptides will be applicable not only for BNCT but also for a wide variety of therapeutic methodologies. |
| 巻・号 | 19(4) |
| ページ | 1135-1145 |
| 公開日 | 2022-4-4 |
| DOI | 10.1021/acs.molpharmaceut.1c00882 |
| PMID | 35298163 |
| MeSH | Boron Compounds Boron Neutron Capture Therapy* / methods Cell-Penetrating Peptides* Extracellular Vesicles* Neutrons |
| IF | 4.321 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | X(Twitter) |
| 各媒体での言及数の合計 | 1 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | HeLa |